key: cord-0022951-h04i62de
authors: Lee, Sharen; Jeevaratnam, Kamalan; Liu, Tong; Chang, Dong; Chang, Carlin; Wong, Wing Tak; Wong, Ian Chi Kei; Lip, Gregory Y. H.; Tse, Gary
title: Risk stratification of cardiac arrhythmias and sudden cardiac death in type 2 diabetes mellitus patients receiving insulin therapy: A population‐based cohort study
date: 2021-09-21
journal: Clin Cardiol
DOI: 10.1002/clc.23728
sha: 59ef5e0268e731e9200ece6f0d4bebd578c764be
doc_id: 22951
cord_uid: h04i62de

INTRODUCTION: Metabolic abnormalities may exacerbate the risk of adverse outcomes in patients with type 2 diabetes mellitus. The present study aims to assess the predictive value of HbA1c and lipid variability on the risks of sudden cardiac death (SCD) and incident atrial fibrillation (AF). METHODS: The retrospective observational study consists of type 2 diabetic patients prescribed with insulin, who went to publicly funded clinics and hospitals in Hong Kong between January 1, 2009 and December 31, 2009. Variability in total cholesterol, low‐density lipoprotein‐cholesterol (LDL‐C), high‐density lipoprotein‐cholesterol (HDL‐C), triglyceride, and HbA1c were assessed through their SD and coefficient of variation. The primary outcomes were incident (1) ventricular tachycardia/ventricular fibrillation, actual or aborted SCD and (2) AF. RESULTS: A total of 23 329 patients (mean ± SD age: 64 ± 14 years old; 51% male; mean HbA1c 8.6 ± 1.3%) were included. On multivariable analysis, HbA1c, total cholesterol, LDL‐C and triglyceride variability were found to be predictors of SCD (p < .05). CONCLUSION: HbA1c and lipid variability were predictive of SCD. Therefore, poor glucose control and variability in lipid parameters in diabetic patients are associated with aborted or actual SCD. These observations suggest the need to re‐evaluate the extent of glycemic control required for outcome optimization.

cholesterol, LDL-C and triglyceride variability were found to be predictors of SCD (p < .05).

Conclusion: HbA1c and lipid variability were predictive of SCD. Therefore, poor glucose control and variability in lipid parameters in diabetic patients are associated with aborted or actual SCD. These observations suggest the need to re-evaluate the extent of glycemic control required for outcome optimization. accounting for approximately 25% of deaths of cardiovascular origin. 1 By contrast, atrial fibrillation (AF), the most common sustained arrhythmia amongst adults, is increasingly prevalent around the world, particularly amongst developed countries. 2, 3 Significant increases in morbidity and mortality amongst large-scale epidemiological studies have been demonstrated amongst AF patients, including an increase in SCD risk. [4] [5] [6] [7] Furthermore, type 2 diabetes mellitus increases the risk of SCD, as demonstrated by a recent meta-analysis of populationbased prospective studies. 8 With the global shift towards a more personalized approach in the management of diabetes, there is an increasing interest in exploring the application of new parameters, such as HbA1c and lipid variability, to better monitor disease progression and evaluate the prognosis. Although the exact mechanisms remain unclear, increased long-term glycemic and lipid variability is hypothesized to lead to endothelial dysfunction via an increase in oxidative stress. [9] [10] [11] Since hemoglobin has an average lifespan of 100 days, HbA1c can reflect glycemic control in recent months. Therefore, HbA1c variability is not affected by short-term glycemic changes due to diet and medication changes, thus it is a better representation of long-term glycemic variation. However, existing studies have focused on risk prediction of allcause mortality and general cardiovascular adverse events, [12] [13] [14] [15] [16] with a limited number of studies exploring specifically arrhythmic risks amongst diabetics. Moreover, those type 2 diabetics who are partially or fully dependent on insulin are more likely to have severe disease and may be at higher risks of arrhythmias.

The aim of the present study was to assess the predictive value of HbA1c and lipid variability towards aborted or successful SCD, as well as incident AF in type 2 diabetic patients receiving insulin therapy. [17] [18] [19] [20] including diabetes mellitus, 21 in the past.

Clinical and biochemical data of the present cohort were extracted from CDARS. The outcomes of the present study are the occurrence of SCD and AF from January 1, 2009 to December 31, 2019. SCD is defined as episodes of VT, VF, or nonspecific cardiac arrest, which were diagnosed under clinical judgment with electrocardiographic or biochemical findings and subsequently coded into hospital records.

Both aborted and actual SCD events were included. VT/VF on electrophysiological study is not included. Hypoglycemia-induced cases of SCD or AF were defined as cases with dextrose infusion during the admission episode or had blood glucose measured ≤3.9 mg/mmol. Demographic details, including age and sex, were extracted. Patients were categorized into four groups based on their age: below age 55, between ages 55 and 64, between ages 65 and 74, above and include age 75. The number of baseline acute hospitalization episodes between January 1, 2004 and December 31, 2008 was also obtained. 

Statistical analysis was performed using R Studio, and statistical significance was defined as p value <.05. Kaplan-Meier survival curve was used to portray the difference in actual or aborted SCD and AF survival between patients of different age groups, with the statistical significance of the intergroup difference evaluated using the log-rank test. Temporal variability of HbA1c and lipid indices were evaluated using calculated parameters of SD and coefficient of variation (CV). CV was measured by multiplying 100-fold of the value calculated by the ratio SD and mean. SD and CV were used to measure variability since they were less affected by outliers. Whilst SD is independent of the mean, CV is independent of the scale thus more sensitive to small changes to the mean. To identify predictors for shorter time to aborted or actual SCD and AF occurrence, univariable Cox regression was first applied to clinical and biochemical parameters. Patients with missing data were excluded from the analysis. Furthermore, due to their limited prescription towards the study cohort, GLPA and meglitinide were not included. Subsequently, parameters with p value <0.10 were included in the multivariable Cox regression model. Only patients with no missing data for the selected parameters, and at least three measurements for the selected variability predictors, were included in the multivariate models. No data imputation was performed.

The inter-relations between HbA1c and lipid variability with intermittent hypoglycemia were evaluated using logistic and Poisson regression. Logistic regression was also used to examine the relationship between baseline hypoglycemia frequency and (1) occurrence of SCD/AF or (2) aborted or actual SCD/AF episodes that were associated with hypoglycemia. Odds ratios (ORs) were reported from logistic and Poisson regression, whereas hazard ratios were reported from Cox regression, along with the 95% confidence intervals.

The present study included 23 329 patients (mean age = 64.3 ± 13.8, male = 50.8%, average mean HbA1c = 8.6 ± 1.3%, all-cause mortality = 50.5%). The cohort was divided into four age groups: <55 (n = 5511), 55-64 (n = 5745), 65-74 (n = 6032), >75 (n = 6041), with a significant intergroup difference in survival for both aborted or actual SCD (p < .0001) and incident AF (p < .0001; Figure 1A 

In the present cohort, 10.3% of patients suffered from at least one SCD event, and 7.7% suffered from AF. Amongst these cases, 25 and 10 cases of patients experiencing aborted or actual SCD and AF were associated with hypoglycemia on admission, respectively. Supplementary Table 4 , where several significant pre- 

The present study demonstrated the following major findings: (1) variability is associated with hypoglycemia frequency. To the best of our knowledge, the present study is the first to report an association between increased variability in HbA1c and lipid markers with increased risk for VT/VF/SCD amongst diabetic patients.

The prognostic values of HbA1c and lipid variability have been increasingly explored over the past decades. However, prior studies have mostly focused on the prediction of all-cause mortality or cardiovascular events 12, 22 with only a limited number of studies focusing on arrhythmic or SCD outcomes. 23 Although the underlying pathophysiology remains incompletely elucidated, there are several possible contributing factors towards the increased arrhythmic risk amongst patients with high glycemic and lipid variability. First, increased glycemic variability is found to be associated with QTc prolongation and increased QTc dispersion, which greatly elevates the risk of ventricular tachyarrhythmia. 24, 25 There is evidence suggesting that QTc prolongation may be triggered by spontaneous hypoglycemia due to underlying coronary atherosclerosis or cardiac autonomic neuropathy. [26] [27] [28] [29] Antidiabetic agent use may also play a role in the prognostic value of glycemic variability. Biguanide users are likely more stable or earlier in the disease course, thus have a lower cardiovascular disease burden. Sulphonylurea use, which was predictive of SCD in the present study, is known to have an increased risk of hypoglycemia. 30 In addition, it has been reported human ether-a-go-go-related gene (hERG) channel inhibitory effects of some sulphonylurea, which can lead to QT prolongation. 31 Amongst patients on insulin, who have more labile glucose control, the spontaneous glycemic fluctuations can induce the occurrence of arrhythmia. Unfortunately, continuous blood glucose monitoring was not available in the present study to demonstrate the association between spontaneous glycemic changes and arrhythmic episodes.

Furthermore, structural remodeling as a result of chronic hyperglycemia is also involved in the pathogenesis. [32] [33] [34] [35] [36] [37] HbA1c variability has been associated with remodeling and fibrosis of the atria and ventricles, which could be arrhythmogenic. [38] [39] [40] In a recent nationwide observational study, an association between high lipid variability and increased risk of new-onset AF was reported, and statins protected against AF development via the reduction in adverse atrial remodeling. 41 Moreover, frequent intermittent hypoglycemia can induce the release of reactive oxygen species, 42 thereby leading to increased oxidative stress, chronic inflammation, and endothelial dysfunction. 43 Hypoglycemia itself is arrhythmogenic and can reduce the myocardial tolerance to ischemia and reperfusion injuries. 44, 45 Similar to glycemic variability, the increase in oxidative stress with fluctuations in lipid levels due to atherogenic substance release from unstable plaque is hypothesized to underlie the increased arrhythmic risk. 12 Indeed, glycemic fluctuations were found to increase the formation of atherosclerotic plaques and thinning the fibrous cap, which suggests that intermittent hypoglycemia may contribute to lipid variability as well. 46 It should be noted that whilst triglyceride and HDL-C variability are dependent on glycemic control and other lifestyle factors, the use of statin plays a significant role in LDL-C variability. The significant interpersonal variability, as well as the varying effects between different types of statins on LDL-C variability, reflects the need for further research on the area. 47, 48 The change in HbA1c and lipid variability from predictive of SCD, in univariable analysis, to being protective under multivariable analysis, can be attributed to several causes. The limitation of cohort size and multivariate analysis may have selected for patients of more advanced disease and undergone aggressive control. Given that a Jshaped association between adverse outcome and both glycemic and lipid indices have been described, patients with high variability that returned to the optimal glycemic and lipid range would have had a better prognosis. 16, 49, 50 Indeed, the duration of exposure to an optimal glycemic range is inversely associated with diabetic retinopathy progression, even after accounting for the effects of glycemic variability. 51 Additionally, Ceriello et al. reported that patients with elevations in both HbA1c and HDL-C variability were at higher risk for diabetic nephropathy than those with high variability in only one variable, highlighting the interacting effects between variability markers. 52 Therefore, the protective value may be a result of inevitable selection bias, the protective effects of pharmacotherapy, and the interactions between different indices. 53,54

There are four major strengths for the present study: (1) However, several limitations should be recognized. Firstly, the cohort was limited to type 2 diabetic patients prescribed with insulin, which can limit the generalizability of the findings. Given that insulin is only prescribed for diabetic patients in later stages, an advanced disease state can be inferred for the selected patients. Secondly, the observational nature of the present study leads to inevitable errors from missing data, coding errors, and under-coding. A causational relationship cannot be established from the findings of the observational study, which can only demonstrate associations. Furthermore, unfortunately, ICD coding does not reflect the frequency of events, thus the frequency of SCD events was not evaluated. The coding also does not reflect whether the VT is sustained or associated with hemodynamic collapse. It is based on the assumption that coded VT is clinically significant as nonsustained VT would be clinically irrelevant thus not coded into the database. It should be emphasized that a diagnosis of VT is not the same as SCD, hence the effect of long-term glycemic variability on the risk of SCD should be interpreted with caution.

Novel therapies, such as GLPA (n = 9) and SGLT-2 transporter inhibitor (n = 0), were not assessed due to the fact that this retrospective study recruited patients in the year 2009, at which these agents were not yet developed. Finally, data on blood pressure, body mass index, echocardiogram, severity of HF and lifestyle were absent, which can affect the patients' cardiovascular health.

Poor glucose control and variability in lipid parameters in diabetic patients are associated with SCD. These observations suggest the need to re-evaluate the extent of glycemic control required for outcome optimization. Further studies on the predictive value of variability in other glycemic measures, such as fasting and random blood glucose, in addition to other methods of measuring variability, should be performed to further examine the predictiveness of glycemic variability towards arrhythmias in diabetic patients.

No conflicts of interest.

The deidentified dataset arising from this study is available upon request.

ORCID

ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)

Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study

Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century

Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study

Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study

Usefulness of the CHA2DS2-VASc score to predict the risk of sudden cardiac death and ventricular arrhythmias in patients with atrial fibrillation

Risk and prediction of sudden cardiac death and ventricular arrhythmias for patients with atrial fibrillationa

Diabetes mellitus and the risk of sudden cardiac death: a systematic review and meta-analysis of prospective studies

The relationship between glucose variability and insulin sensitivity and oxidative stress in subjects with prediabetes

Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes

HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms

Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial

Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus

Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study

Development of a predictive risk model for all-cause mortality in patients with diabetes in Hong Kong

Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study

Relationship between angiotensinconverting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease

Interaction effects between angiotensinconverting enzyme inhibitors or angiotensin receptor blockers and steroid or antiviral therapies in COVID-19: a population-based study

Hospitalization and mortality in patients with heart failure treated with Sacubitril/valsartan vs. Enalapril: a real-world, population-based study

Association of NPAC score with survival after acute myocardial infarction

Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning

Relationship of HbA1c variability, absolute changes in HbA1c, and all-cause mortality in type 2 diabetes: a Danish population-based prospective observational study

Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death

The effect of glucose variability on QTc duration and dispersion in patients with type 2 diabetes mellitus

The association of long-term glycaemic variability versus sustained chronic hyperglycaemia with heart rate-corrected QT interval in patients with type 2 diabetes

Prolonged cardiac repolarisation during spontaneous nocturnal hypoglycaemia in children and adolescents with type 1 diabetes

Association between the corrected QT intervals and combined intimalmedial thickness of the carotid artery in patients with type 2 diabetes

QT interval, corrected for heart rate, is associated with HbA1c concentration and autonomic function in diabetes

Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: a systematic review and meta-analysis

Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias

Human ether-a-go-go-related (HERG) gene and ATPsensitive potassium channels as targets for adverse drug effects

Empagliflozin, a sodium glucose cotransporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes

The influence of type 2 diabetes on left atrial remodeling

Wenxin Keli regulates mitochondrial oxidative stress and homeostasis and improves atrial remodeling in diabetic rats

Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits

PKCβ/NF-κB pathway in diabetic atrial remodeling

Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats

Impact of HbA1c variability on subclinical left ventricular remodeling and dysfunction in patients with type 2 diabetes mellitus

Molecular and electrophysiological mechanisms underlying cardiac Arrhythmogenesis in diabetes mellitus

Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation

Reactive oxygen species, endoplasmic reticulum stress and mitochondrial dysfunction: the link with cardiac Arrhythmogenesis

Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA1c levels

Effects of hypoglycemia on myocardial susceptibility to ischemia-reperfusion injury and preconditioning in hearts from rats with and without type 2 diabetes

Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study

Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography

LDL cholesterol variability in patients with type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation

Interindividual variation in low-density lipoprotein cholesterol level reduction with Evolocumab: an analysis of FOURIER trial data

U-shaped association between lowdensity lipid cholesterol and diabetes mellitus in patients with hypertension

Serum lipids and mortality in an American Indian population: a longitudinal study

Association of Time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes

Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes

Safety and efficacy of statin therapy

Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies